Improving Treatment for IPF
Trial Objectives
Researchers want to know if a new medication, Saracatinib, is a more safe and effective treatment for Idiopathic Pulmonary Fibrosis (IPF) when compared to treatments that are currently available.
Who Can Participate
Adults 40 years of age and older.
Age: 40+ Gender: Any
Estimated Time Commitment
Not Specified
Time Commitment Details
Visits will take two to four hours.
Payment & Reimbursement
Payment: Not Provided
Travel Reimbursement: Not Available
Trial Location
National Jewish Main Campus, Denver, CO
Trial Sponsors
National Institutes of Health
Principal Investigators
Gregory P. Downey, MD, FRCPC
Co-Investigators
Kevin K. Brown, MD